Related Experiment Video
Updated: Feb 28, 2026
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Hepatobiliary disease in inflammatory bowel disease
1Mayo Clinic, Rochester, Minnesota, USA.
Insights
Primary sclerosing cholangitis (PSC) is closely linked with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC). While not causative, they share common pathways, impacting patient risk for other conditions.
Area of Science:
- Hepatology
- Gastroenterology
- Immunology
Background:
- Primary sclerosing cholangitis (PSC) is the most prevalent hepatobiliary disease associated with inflammatory bowel disease (IBD).
- Approximately 5% of ulcerative colitis (UC) patients have PSC, and most PSC patients develop IBD, typically UC.
- PSC and UC are considered associated diseases, likely sharing common pathogenic mechanisms rather than a direct causal link.
Purpose of the Study:
- To explore the relationship between PSC and IBD, focusing on clinical, biochemical, and histological features.
- To investigate the implications of colectomy in patients with PSC and UC.
- To identify serologic markers for PSC and associated complications like cholangiocarcinoma.
Main Methods:
- Comparative analysis of clinical, biochemical, cholangiographic, and histological features in patients with PSC alone versus PSC with IBD.
- Evaluation of the impact of colectomy on PSC progression in patients with concurrent PSC and UC.
- Identification and assessment of serologic markers in patients with PSC, with or without UC.
Main Results:
- PSC in patients with or without IBD exhibits similar clinical, biochemical, cholangiographic, and histological characteristics.
- Colectomy does not affect PSC progression in patients with PSC and UC.
- Serologic markers are being identified for PSC, including those for cholangiocarcinoma.
- Patients with PSC and UC have an increased risk of both colon and biliary malignancies.
Conclusions:
- PSC and UC are strongly associated, sharing underlying pathogenic mechanisms.
- Management strategies for PSC and UC need to consider the increased risk of malignancy.
- Liver transplantation remains a life-saving option for advanced PSC, while medical therapies are under investigation.
Abstract:
PSC is the most common and most important hepatobiliary disease seen in association with IBD. Approximately 5% of all patients with CUC have PSC, and most patients with PSC ultimately develop IBD, usually CUC. PSC and CUC appear to be associated diseases-one does not cause the other, but common pathogenic mechanisms are likely involved. PSC alone does not differ from PSC with IBD with regard to clinical, biochemical, cholangiographic, and hepatic histologic features. There is an overlap syndrome of CAH and PSC in patients with CUC suggesting that patients with CAH and CUC should have a cholangiogram. Colectomy in patients with PSC and CUC does not influence the PSC and, if done for colitic indications, should be accompanied by an ileal pouch-anal anastomosis. Serologic markers are being identified, which are frequently found in PSC with or without CUC, including markers for the dreaded complication of cholangiocarcinoma. Unfortunately, patients with PSC and CUC are doubly at risk for malignancies of the colon and biliary system. Medical therapies are being assessed that may beneficially affect both PSC and CUC, and liver transplantation is life-saving for patients with advanced PSC. Although CAH and gallstones are also found in association with IBD, they are much less common and of considerably less clinical importance than PSC associated with IBD.
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF